Trevi Therapeutics, Inc. Common Stock (TRVI) is a publicly traded Healthcare sector company. As of July 21, 2026, TRVI trades at $17.72 with a market cap of $2.71B and a P/E ratio of -37.26. TRVI moved +5.61% today. Year to date, TRVI is +33.52%; over the trailing twelve months it is +144.46%. Its 52-week range spans $2.36 to $20.22. Analyst consensus is strong buy with an average price target of $24.43. Rallies surfaces TRVI's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies AI research for TRVI combines live market data, fundamentals, news, analyst context, hedge fund holdings, politician trades, insider activity, and risk factors into a ticker-specific research workflow.
| Metric | Value |
|---|---|
| Price | $17.72 |
| Market Cap | $2.71B |
| P/E Ratio | -37.26 |
| EPS | $-0.47 |
| Dividend Yield | 0.00% |
| 52-Week High | $20.22 |
| 52-Week Low | $2.36 |
| Volume | 719.99K |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-47.91M |
| Gross Margin | 0.00% |
7 analysts cover TRVI: 0 strong buy, 7 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $24.43.